What is MSLE (MSLE) stock price today?

MSLE (MSLE) is currently trading at $10.03, down 0.4% today.

What is MSLE P/E ratio?

MSLE's P/E ratio is 3.47. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is MSLE return on equity (ROE)?

MSLE's return on equity (ROE) is -42.55%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is MSLE's market cap?

MSLE has a market capitalization of $12.92M.

NASDAQ · Medical - Pharmaceuticals

MSLE (MSLE) Stock

$10.03 -0.40% NASDAQ: MSLE Healthcare

Valuation

Metric	Value
Price	$10.03
Market Cap	$12.92M
P/E Ratio	3.47
P/B Ratio	0.20
P/S Ratio	0.00
EPS (TTM)	$2.09
52-Week High	$13.39
52-Week Low	$4.55
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-42.55%
ROA	-39.22%
ROCE	-40.43%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	12.75

Annual Financials (USD)

Metric	2021	2022	2023	2024
Revenue	$0	$0	$0	$0
Operating Profit	$0	$0	$-12.0M	$-19.0M
Net Profit	$-12.0M	$-8.0M	$-12.0M	$-20.0M
EPS	$-6.02	$-2.83	$-1.63	$2.09
Op Margin	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024
Total Assets	$10.0M	$5.0M	$33.0M	$51.0M
Total Liabilities	$2.0M	$2.0M	$3.0M	$4.0M
Cash	$4.0M	$1.0M	$17.0M	$40.0M
Borrowings	$0	$0	$0	$0

Latest News

Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update MarketBeat · Jul 10, 2026 Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence Benzinga · Jul 8, 2026 Satellos Says Interim Phase 2 Data Shows SAT-3247 Improves Muscle Measures in Adult DMD Patients MT Newswires · Jul 8, 2026 Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 GlobeNewswire · Jul 8, 2026 Satellos Bioscience up near 10% as SAT-3247 Granted FDA Fast Track Designation MT Newswires · Jun 29, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024
Operating Cash Flow	$-4.0M	$-4.0M	$0	$-17.0M
Investing Cash Flow	$1.0M	$0	$-13.0M	$4.0M
Financing Cash Flow	$0	$0	$-24.0M	$7.0M
Net Cash Flow	$3.0M	$-2.0M	$15.0M	$25.0M
Free Cash Flow	$-4.0M	$-4.0M	$0	$-17.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-22.99%
Quick Ratio	11.13
Interest Coverage	—
Return 1Y	78.72%
Return 3Y	92.39%
Return 5Y	-53.26%

Ownership

Insiders Held6.48%

Institutions Held50.62%

Institutions Float Held54.13%

Institutional Holder	Shares	Report Date
Franklin Resources, Inc.	938,666	2026-03-31
Siren, L.L.C.	892,074	2026-03-31
Vivo Capital, LLC	813,666	2026-03-31
Point72 Asset Management, L.P.	690,778	2026-03-31
Woodline Partners LP	500,432	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$313.33	+0.29%	37.72	$4.60T	0.34%
MSFTMicrosoft Corporation	$499.99	+0.03%	22.95	$3.71T	0.94%
GOOGLAlphabet Inc.	$354.30	-0.96%	27.68	$4.29T	0.23%
AMZNAmazon.com, Inc.	$274.48	+0.82%	28.76	$2.95T	0.00%
METAMeta Platforms, Inc.	$592.10	+0.37%	21.47	$1.51T	0.35%

About MSLE

MSLE is led by CEO Francis Gleeson, employs 14 people, headquartered in CA, publicly traded since 2024.

MSLE stock trades at $10.03 with a market capitalization of $12.92M. The stock is valued at a price-to-earnings (P/E) ratio of 3.47, price-to-book of 0.20, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.55 and $13.39, and currently trades 25.1% below its 52-week high.

On profitability, MSLE generates a return on equity (ROE) of -42.55%, return on capital employed of -40.43%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides